BSL3 Enhancements for RNA Virus Pandemic Preparedness

BSL3 针对 RNA 病毒大流行防范的增强

基本信息

  • 批准号:
    10611745
  • 负责人:
  • 金额:
    $ 399.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-16 至 2025-02-28
  • 项目状态:
    未结题

项目摘要

Program Summary/Abstract The University of Massachusetts Chan Medical School (UMass Chan) seeks NIH G20 funding to repair, renovate, and modernize the existing Biosafety Level 3 (BSL3) and Animal BSL3 (ABSL3) facilities to enhance current research on RNA viruses of pandemic potential. As an internationally recognized leader in infectious disease research, UMass Chan has made pivotal contributions to this field, including work on the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), highly pathogenic avian influenza virus, Newcastle disease virus, and Zika virus. At the start of the coronavirus 2019 (COVID-19) pandemic, we quickly became one of the leading institutes for research and clinical trials on SARS-CoV-2. Our researchers obtained several awards from the NIH, NSF, and Department of Defense, as well as private foundations for these studies. As a leading site for COVID-19 clinical trials, UMass Chan is uniquely poised to bridge clinical and basic research studies on these RNA viruses by enabling essential research on patient samples to complement in vitro and in vivo studies. Our findings can be translated to develop novel prevention and therapeutic strategies leveraging our world-renowned RNA Therapeutics Institute, our Institute for Drug Resistance, and our partnership with MassBiologics for vaccine development, making UMass Chan a powerhouse for bench-to-bedside translational research. The UMass Chan BSL3 Core Laboratories have seen a staggering increase in usage due to the pandemic. Our BSL3 and ABSL3 facilities need major updates and renovations to keep pace with our research programs and continue to provide a safe, modern, and efficient lab for BSL3 work. The last time these facilities were completely renovated was over a decade ago (2003–2005 for our ABLS3 and 2010–2014 for our BSL3). We will modernize the existing BSL3 and ABSL3 facilities by updating the ceiling and ventilation systems, installing new autoclaves, maximizing the existing footprint by removing outdated equipment, and updating cameras for safety. These updates will significantly enhance research on RNA viruses of pandemic potential by addressing deficiencies that have caused prolonged downtime for repairs, and by enhancing the resilience of critical building systems. Our UMass Chan Facilities and Campus Services team has extensive experience executing design, renovations, and oversight of the operations and have worked with the NIH on previous G20 and C06- funded improvements to our facilities. The G20 funding will also be backed by strong institutional support for this project and a commitment to fully equip the updated space with state-of-the-art scientific instruments and other equipment needed to maintain the productivity of currently funded and future research on SARS-CoV-2 and other BSL3-level RNA viral pathogens. With G20 funding, our BSL3 and ABSL3 labs can get much- needed updates to support our faculty as they continue to make ground-breaking fundamental discoveries with translational potential to address SARS-CoV-2 and other RNA viruses of pandemic potential.
项目概要/摘要 马萨诸塞州陈医学院(UMass Chan)寻求NIH G20资助修复, 更新和现代化现有的生物安全3级(BSL 3)和动物BSL 3(ABSL 3)设施, 目前对可能导致大流行的RNA病毒的研究。作为国际公认的传染病领域的领导者, 疾病研究,马萨诸塞大学陈作出了关键贡献,这一领域,包括工作的严重急性 呼吸道综合征冠状病毒2型,高致病性禽流感病毒,纽卡斯尔病 寨卡病毒是什么?在2019冠状病毒病(COVID-19)大流行开始时,我们迅速成为 在SARS-CoV-2的研究和临床试验方面处于领先地位。我们的研究人员获得了多个奖项, 美国国立卫生研究院,国家科学基金会,国防部,以及这些研究的私人基金会。作为领先的网站, COVID-19临床试验,马萨诸塞大学陈是唯一准备桥梁临床和基础研究研究,这些 通过对患者样本进行必要的研究,以补充体外和体内研究。我们 研究结果可以转化为开发新的预防和治疗策略, RNA治疗研究所,我们的耐药性研究所,以及我们与MassBiologics的疫苗合作伙伴关系 发展,使马萨诸塞大学陈一个发电站的板凳到床边的转化研究。 麻省大学陈BSL 3核心实验室的使用量因疫情而大幅增加。 我们的BSL 3和ABSL 3设施需要进行重大更新和翻新,以跟上我们的研究计划 并继续为BSL 3工作提供安全、现代化和高效的实验室。上次这些设施 十多年前进行了全面翻修(2003-2005年为我们的ABLS 3,2010-2014年为我们的BSL 3)。我们 将通过更新天花板和通风系统,安装 新的高压灭菌器,通过拆除过时的设备最大限度地提高现有的足迹,并更新摄像机, 安全为代价的这些更新将通过解决以下问题,大大加强对具有大流行潜力的RNA病毒的研究: 这些缺陷导致维修停机时间延长,并通过提高关键 建筑系统。我们的马萨诸塞大学陈设施和校园服务团队有丰富的经验,执行 设计,翻新和监督的运作,并已与美国国立卫生研究院在以前的G20和C 06- 资助我们的设施改进。20国集团的资金还将得到强有力的机构支持, 这个项目和承诺,以充分装备最先进的科学仪器, 维持目前资助的SARS-CoV-2研究和未来研究的生产力所需的其他设备 和其他BSL 3水平的RNA病毒病原体。有了G20的资助,我们的BSL 3和ABSL 3实验室可以获得更多- 需要更新,以支持我们的教师,因为他们继续作出突破性的基本发现, 翻译潜力,以解决SARS-CoV-2和其他RNA病毒的流行潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hardy Kornfeld其他文献

Hardy Kornfeld的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hardy Kornfeld', 18)}}的其他基金

Lung-Protective Mechanisms of Metformin in TB
二甲双胍治疗结核病的肺保护机制
  • 批准号:
    10556391
  • 财政年份:
    2021
  • 资助金额:
    $ 399.42万
  • 项目类别:
Lung-Protective Mechanisms of Metformin in TB
二甲双胍治疗结核病的肺保护机制
  • 批准号:
    10338184
  • 财政年份:
    2021
  • 资助金额:
    $ 399.42万
  • 项目类别:
Sirtuins and Host Metabolism in TB Pathogenesis and Treatment
Sirtuins 和宿主代谢在结核病发病机制和治疗中的作用
  • 批准号:
    10208211
  • 财政年份:
    2021
  • 资助金额:
    $ 399.42万
  • 项目类别:
Sirtuins and Host Metabolism in TB Pathogenesis and Treatment
Sirtuins 和宿主代谢在结核病发病机制和治疗中的作用
  • 批准号:
    10620121
  • 财政年份:
    2021
  • 资助金额:
    $ 399.42万
  • 项目类别:
Sirtuins and Host Metabolism in TB Pathogenesis and Treatment
Sirtuins 和宿主代谢在结核病发病机制和治疗中的作用
  • 批准号:
    10390487
  • 财政年份:
    2021
  • 资助金额:
    $ 399.42万
  • 项目类别:
Trial of Metformin for TB/HIV Host-directed Therapy
二甲双胍用于结核病/艾滋病毒宿主定向治疗的试验
  • 批准号:
    10644973
  • 财政年份:
    2019
  • 资助金额:
    $ 399.42万
  • 项目类别:
Trial of Metformin for TB/HIV Host-directed Therapy
二甲双胍用于结核病/艾滋病毒宿主定向治疗的试验
  • 批准号:
    9926218
  • 财政年份:
    2019
  • 资助金额:
    $ 399.42万
  • 项目类别:
Determinants of Tuberculosis Severity
结核病严重程度的决定因素
  • 批准号:
    9030009
  • 财政年份:
    2016
  • 资助金额:
    $ 399.42万
  • 项目类别:
Planning for the Metformin for TB/HIV Host-directed Therapy (METHOD) Trial
规划二甲双胍用于结核病/艾滋病毒宿主定向治疗 (METHOD) 试验
  • 批准号:
    9138531
  • 财政年份:
    2016
  • 资助金额:
    $ 399.42万
  • 项目类别:
Acquired susceptibility to pulmonary TB
获得性肺结核易感性
  • 批准号:
    7460497
  • 财政年份:
    2008
  • 资助金额:
    $ 399.42万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 399.42万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 399.42万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 399.42万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 399.42万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 399.42万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 399.42万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 399.42万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 399.42万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 399.42万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 399.42万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了